Opinion: PARP inhibitors in cancer—what do we still need to know?

PARP inhibitors (PARPi) have been demonstrated to exhibit profound anti-tumour activity in individuals whose cancers have a defect in the homologous recombination DNA repair pathway. Here, we describe the current consensus as to how PARPi work and how drug resistance to these agents emerges. We disc...

Descripción completa

Detalles Bibliográficos
Autores principales: Wicks, Andrew J., Krastev, Dragomir B., Pettitt, Stephen J., Tutt, Andrew N. J., Lord, Christopher J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Royal Society 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9326299/
https://www.ncbi.nlm.nih.gov/pubmed/35892198
http://dx.doi.org/10.1098/rsob.220118

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9326299/
https://www.ncbi.nlm.nih.gov/pubmed/35892198
http://dx.doi.org/10.1098/rsob.220118

Ejemplares similares